Gaucher
Were you expecting leukaemia?
Think Gaucher Disease
A Diagnostic Algorithm for Adults1
Understanding Gaucher Disease Type 1
GD is the most common LSD caused by a deficiency in glucocerebrosidase enzyme. GD patients may experience 10 years of diagnostic delay.
Test for diagnosis
- Enzyme activity test on DBS
- Whole blood sample analysis to confirm diagnosis
References
- Mistry PK, et al. Am J Hematol. 2011. 86(1):110–115.
- Mehta A. Eur J Intern Med. 2006;17 Suppl: S2–S5. REFERENCES
- Hannah-Shmouni F, et al. Mol Genet Metab Rep. 2019;18:19–21.
One JLT Building, Level 3, Jumeirah Lake Towers, PO Box 53899, Dubai, UAE For further medical information, please contact: For UAE 800 MEDICAL Toll Free Number. For all Gulf countries +971 565776791 or email: medical-information.gulf@sanofi.com.
Full prescribing information is available upon request.
To Report adverse events please call: +971 561747001 or email Gulf.Pharmacovigilance@sanofi.com
www.sanofi.com
To report any side effect(s): Saudi Arabia: The National Pharmacovigilance and Drug Safety Centre (NPC): SFDA call center: 19999 • E-mail: npc.drug@sfda.gov.sa • Website: https://ade.sfda.gov.sa/
Full Prescribing Information is available upon request:
SANOFI, Kingdom of Saudi Arabia, P.O. Box 9874, Jeddah 21423, K.S.A. Tel: +966-12-669-3318, Fax: +966-12-663-6191
For Medical Information, Please contact: +966-12-669-3318, ksa.medicalinformation@sanofi.com
For Pharmacovigilance, Please contact: +966-54-428-4797, ksa_pharmacovigilance@sanofi.com
To report any Product Technical Complaint, please contact SANOFI Quality Department:
Email: quality.greatergulf@Sanofi.com
www.sanofi.com.sa
Were you expecting leukaemia?
Think Gaucher Disease
A Diagnostic Algorithm for Paediatric Patients1
Understanding Gaucher Disease Type 1
GD is the most common LSD caused by a deficiency in glucocerebrosidase enzyme. GD patients may experience 10 years of diagnostic delay.
Test for diagnosis
- Enzyme activity test on DBS
- Whole blood sample analysis to confirm diagnosis
References
- Di Rocco M, et al. Pediatric Blood Cancer 2014. 61(11):1905–1909.
- Mehta A. Eur J Intern Med. 2006;17 Suppl: S2–S5.
- Hannah-Shmouni F, et al. Mol Genet Metab Rep. 2019;18:19–21.
One JLT Building, Level 3, Jumeirah Lake Towers, PO Box 53899, Dubai, UAE For further medical information, please contact: For UAE 800 MEDICAL Toll Free Number. For all Gulf countries +971 565776791 or email: medical-information.gulf@sanofi.com.
Full prescribing information is available upon request.
To Report adverse events please call: +971 561747001 or email Gulf.Pharmacovigilance@sanofi.com
www.sanofi.com
To report any side effect(s): Saudi Arabia: The National Pharmacovigilance and Drug Safety Centre (NPC): SFDA call center: 19999 • E-mail: npc.drug@sfda.gov.sa • Website: https://ade.sfda.gov.sa/
Full Prescribing Information is available upon request:
SANOFI, Kingdom of Saudi Arabia, P.O. Box 9874, Jeddah 21423, K.S.A. Tel: +966-12-669-3318, Fax: +966-12-663-6191
For Medical Information, Please contact: +966-12-669-3318, ksa.medicalinformation@sanofi.com
For Pharmacovigilance, Please contact: +966-54-428-4797, ksa_pharmacovigilance@sanofi.com
To report any Product Technical Complaint, please contact SANOFI Quality Department:
Email: quality.greatergulf@Sanofi.com
www.sanofi.com.sa
.png0/jcr:content/Asset%201%20(1).png)
